Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Zelira Therapeutics ( (AU:ZLD) ) is now available.
Zelira Therapeutics Limited announced the cessation of 125,723 securities due to the expiry of options or other convertible securities without exercise or conversion. This development may impact the company’s capital structure and could influence investor perceptions and market positioning as the company continues its strategic initiatives.
The most recent analyst rating on (AU:ZLD) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Zelira Therapeutics stock, see the AU:ZLD Stock Forecast page.
More about Zelira Therapeutics
Zelira Therapeutics Limited is a company operating in the pharmaceutical industry, focusing on the development and commercialization of cannabinoid-based medicines. The company is known for its innovative therapies targeting various medical conditions, leveraging its expertise in cannabinoid formulations to address unmet clinical needs.
Average Trading Volume: 4,399
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$4.16M
For detailed information about ZLD stock, go to TipRanks’ Stock Analysis page.